I just looked into Progenity's recent patent involving its drug device-delivered versions of Xeljanz and Humira for ulcerative colitis (PGN-600 and PGN-001). This technology will allow these medications to be taken orally rather than as an injection to both increase patient satisfaction and decrease systemic toxicities. I will be short and sweet..